Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE).

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Designing Consent Processes for Research With Older Adults Who May Lack Decisional Capacity: A Guide for Investigators.

Journal of the American Geriatrics Society·2026
Same author

Four Common Beliefs About Patient Memory Evaluations: Who Has Them and What Modifies Them?

American journal of Alzheimer's disease and other dementias·2026
Same author

Expert consensus on communicating tau PET results to persons living with MCI or dementia: Findings from a modified Delphi study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Ambiguous Loss.

JAMA·2026
Same author

Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress.

JAMA network open·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Megan Zhang1, Abigail Perelman2, Cameron Coykendall2

  • 1University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Plasma p-tau181 testing significantly boosts clinician confidence in diagnosing Alzheimer's disease (AD). This blood test helps reclassify diagnoses and guides patient management, improving early and accurate Alzheimer's disease detection.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarker Research
  • Diagnostic Medicine

Background:

  • Early and accurate diagnosis of Alzheimer's disease (AD) is crucial for timely care.
  • Blood-based biomarkers, like plasma p-tau181, offer accessible alternatives to traditional diagnostic methods.
  • The impact of plasma p-tau181 on clinical decision-making requires further investigation.

Purpose of the Study:

  • To evaluate how plasma p-tau181 test results influence diagnosis, clinician confidence, and patient management.
  • To assess the utility of plasma p-tau181 as a diagnostic tool in a memory center setting.
  • To understand the role of plasma p-tau181 in distinguishing AD from non-AD conditions.

Main Methods:

  • Utilized the LucentAD plasma p-tau181 test with defined sensitivity and specificity.
  • Enrolled patients with mild cognitive impairment or dementia without prior AD biomarker diagnosis.
  • Collected clinician survey data pre- and post-testing, supplemented by chart abstraction.

Main Results:

  • Plasma p-tau181 testing led to significant increases in clinician diagnostic confidence (p < 0.001).
  • Test results informed diagnostic reclassifications for both AD and non-AD conditions.
  • Disclosure of results prompted medication adjustments, new consultations, and further diagnostic testing, including lumbar punctures and PET scans in some cases.

Conclusions:

  • Plasma p-tau181 testing is a valuable tool for enhancing diagnostic confidence in Alzheimer's disease.
  • The test effectively informs clinical decisions, aiding in the differentiation between AD and other neurodegenerative conditions.
  • This blood biomarker facilitates more accurate and timely diagnosis, potentially improving patient care pathways.